Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists
Lin, C.-H., Peng, Y.-H., Coumar, M.S., Chittimalla, S.K., Liao, C.-C., Lyn, P.-C., Huang, C.-C., Lien, T.-W., Lin, W.-H., Hsu, J.T.-A., Cheng, J.-H., Chen, X., Wu, J.-S., Chao, Y.-S., Lee, H.-J., Juo, C.-G., Wu, S.-Y., Hsieh, H.-P.(2009) J Med Chem 52: 2618-2622
- PubMed: 19301897 
- DOI: https://doi.org/10.1021/jm801594x
- Primary Citation of Related Structures:  
3GBK - PubMed Abstract: 
Utilizing medicinal chemistry design strategies such as benzo splitting and ring expansion, we converted PPARalpha/gamma dual agonist 1 to selective PPARgamma agonists 19 and 20. Compounds 19 and 20 were 2- to 4-fold better than rosiglitazone at PPARgamma receptor, with 80- to 100-fold PPARgamma selectivity over PPARalpha receptor. X-ray cocrystal studies in PPARgamma and modeling studies in PPARalpha give molecular insights for the improved PPARgamma potency and selectivity for 19 when compared to 1.
Organizational Affiliation: 
Division of Biotechnology and Pharmaceutical Research, National Health Research Institutes, 35 Keyan Road, Zhunan Town, Miaoli County 350, Taiwan, ROC.